- Rorsman Group Research Group
1. Low dosE GlibENclamide in Diabetes Part A (LEGEND-A), NCT02830048
2. Glucagon in MODY, NCT03246828
- Dapagliflozin during Exercise for the Prevention of Hypos (DEPTH)
MBBS, BSc, MRCP (UK)
Clinical Research Fellow & DPhil student
- Honorary Specialty Registrar in Diabetes and Endocrinology
I am a clinical researcher and Specialty Registrar in Diabetes and Endocrinology, with a background in molecular biology. I have been working in the field of islet physiology since 2010 alongside my clinical training, and am currently completing a DPhil in OCDEM. I am also part of the clinical Islet Transplantation programme.
My work focuses on investigating the hormone secretion profiles of islets in various forms of diabetes, with an emphasis on translating in vitro work into pilot clinical trials. I have recently completed a clinical trial (LEGEND-A) of low-dose sulfonylureas in patients with type 2 diabetes, which demonstrated improvement in fasting hyperglucagonemia. I am now extending this work to clinical studies in patients with MODY (maturity onset diabetes of the young) and type 1 diabetes. My aim is to better understand the effect aberrant glucagon secretion has on the pathophysiology of diabetes, and the impact various pharmacological interventions have on this system.
δ-cells and β-cells are electrically coupled and regulate α-cell activity via somatostatin.
Briant LJB. et al, (2017), J Physiol
Islet/stem cell transplantation – what's new?
Spiliotis I. and Johnson PRV., (2017), Paediatrics and Child Health (United Kingdom), 27, 181 - 186
Reversible changes in pancreatic islet structure and function produced by elevated blood glucose
Brereton MF. et al, (2014), DIABETOLOGIA, 57, S93 - S93
Reversible changes in pancreatic islet structure and function produced by elevated blood glucose.
Brereton MF. et al, (2014), Nat Commun, 5
Proceedings of research in clinical practice 2011.
Spiliotis I. et al, (2012), QJM, 105, 593 - 606